NEWS
Semprus Selected as One of “50 Companies To Watch” in MD+DI June Issue
Semprus to Present Pioneering Data at July Center for Biofilm Engineering Science & Technology Meeting
Semprus Organizes Panel Discussion on "Opportunities Presented in Eliminating Device Complications" at 2010 AdvaMed MedTech Conference
ABOUT SEMPRUS BIOSCIENCES
Semprus Biosciences, headquartered in Cambridge, Massachusetts, is a venture-backed biomedical company with a dual mission...
read more
PRODUCT INFORMATION
Semprus BioSciences is developing innovative, multi-faceted approaches to solving complications associated with medical devices. Our Semprus SurfacesTM product platform focuses on controlling the interface between the body and a medical device to address the root cause of many adverse reactions to “foreign” implanted materials (including biofilm formation, thrombosis, and cell overgrowth). Semprus Surfaces™ is based on a bioinert, covalently bonded surface modification that reduces the attachment of bacteria, fungus, platelets, and blood proteins for the life of a device. read more


